Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice
Shuyu Li, Zhouming Xu, Wenhui Ruan, Xiqing Wang, Hongmei Yu, Ming Yi, Peifen Fu · 2026
Read Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice by Shuyu Li, Zhouming Xu, Wenhui Ruan, Xiqing Wang, Hongmei Yu, Ming Yi, Peifen Fu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13563710.txt.
Description
Shuyu Li and six colleagues review antibody-drug conjugates, guided missiles that pair a targeting antibody with a poison payload, and their reshaping of breast cancer care. These drugs reach from late rescue therapy into curative-intent treatment. The 2026 review sorts their targets in a new way, by biology. Some antigens drive the cancer, others mark its tissue lineage or fetal past, and still others sit in the tissue around the tumour. Successive drug generations are traced alongside.
Toxicity management and the ways tumours resist these agents get treatment, since payloads harm healthy tissue and cancers learn to shrug off the warhead. Looking ahead, the authors call for bispecific versions that grip two targets, pairings with immune therapy, and biomarker-guided ordering of drugs across a patient's course. The review aims to give clinicians a map of the field, from mechanism to the sequencing choices that decide outcomes.
Catalog record
| CREATOR | Shuyu Li, Zhouming Xu, Wenhui Ruan, Xiqing Wang, Hongmei Yu, Ming Yi, Peifen Fu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 111880 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |